Charles B. Nguyen, MD

home / authors / charles-b-nguyen-md

Charles B. Nguyen, MD, is an assistant clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Irvine, California.

Articles

Charles B. Nguyen, MD

Dr Nguyen on Treatment Selection Considerations for Non–Clear Cell RCC

Charles B. Nguyen, MD
April 15th 2025

Charles B. Nguyen, MD, details treatment selection in clinical practice for patients with non–clear cell renal cell carcinoma.

Read More

Charles B. Nguyen, MD

Dr Nguyen on Updated NCCN Guidelines for Non–Clear Cell RCC

Charles B. Nguyen, MD
February 7th 2025

Charles B. Nguyen, MD, discusses the updated 2024 NCCN Guidelines and their effect on treatment decisions for non–clear cell RCC.

Read More

Latest Updated Articles

Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Published: December 17th 2024 | Updated: March 26th 2025
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
RLY-2608
Published: January 22nd 2025 | Updated: February 14th 2025
Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial